Fulgent Genetics Posts 48-Cent Loss Per Share in Third Quarter
FLGT sits 39% above its 52-week low of $13.46.
Summary
Fulgent Genetics reported a third-quarter loss of 48 cents per share, on revenue of $90.4 million and a net loss of $13.2 million. That extends a rough stretch: in Q2 2026 gross margin fell to 30%, operating losses nearly doubled, and cash reserves dropped $154 million over six months, with billing system problems weighing on results. The company is small enough that a quarterly loss of this size is material to the equity story, and the burden now falls on management to show the billing issues and margin erosion are contained.
At the time of this announcement, FLGT was trading at $18.66 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $513.4M. The 52-week trading range was $13.46 to $31.04. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.